



Common Drug Review *Patient Group Input Submissions*

fluticasone furoate (Arnuity Ellipta) for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older

Patient group input submissions were received from the following patient groups. Those with permission to post are included in this document.

Asthma Society of Canada/National Asthma Patient Alliance — permission not granted to post.

CADTH received patient group input for this review on or before June 23, 2015.

CADTH posts all patient input submissions to the Common Drug Review received on or after February 1, 2014 for which permission has been given by the submitter.

The views expressed in each submission are those of the submitting organization or individual; not necessarily the views of CADTH or of other organizations. While CADTH formats the patient input submissions for posting, it does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no personal information is included in the submission. The name of the submitting patient group and all conflict of interest information are included in the posted patient group submission; however, the name of the author, including the name of an individual patient or caregiver submitting the patient input, are not posted.

Asthma Society of Canada/National Asthma Patient Alliance

Section 1 — General Information

Name of the drug CADTH is reviewing and indication(s) of interest	Fluticasone Furoate Asthma
Name of patient group	Asthma Society of Canada/National Asthma Patient Alliance
Name of primary contact for this submission:	[REDACTED]
Position or title with patient group	[REDACTED]
Email	[REDACTED]
Telephone number(s)	[REDACTED]
Patient group's contact information:	Asthma Society of Canada
Email	info@asthma.ca
Telephone	416.787.4050
Address	124 Merton Street, Suite 401 Toronto, ON M4S 2Z2
Website	www.asthma.ca

The patient group has not granted permission to post its patient input submission. As announced in [CDR Update — Issue 99](#), when permission is not granted, CADTH will post on its website that a patient submission was received, but it was not posted at the request of the submitter.

The patient input that was provided in this submission, along with all other patient input received for this drug, is included in the summary of patient input that is contained in the posted *CDR Clinical Review Report*.